TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31663980

Group type: EXPERIMENTAL
Intervention: Transcribed list of six treatment recommendations
Number of subjects: 72

Group type: COMPARATOR
Intervention: Verbal discussion of six treatment recommendations
Number of subjects: 72
Study: 28537508

Group type: EXPERIMENTAL
Intervention: LALC
Number of subjects: 105

Group type: COMPARATOR
Intervention: CLC
Number of subjects: 105

Group type: COMPARATOR
Intervention: SILC
Number of subjects: 105
Study: 27179104

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24952869

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg intraoperatively)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 22885981

Group type: EXPERIMENTAL
Intervention: 6.25g polydextrose
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 12.5g polydextrose
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0g polydextrose (control)
Number of subjects: 34
Study: 20634438

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg every 48 hours)
Number of subjects: 434

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 434
Study: 18327780

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector (group II, n = 21)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional surgical techniques (group I, n = 31)
Number of subjects: 52
Study: 17178938

Group type: EXPERIMENTAL
Intervention: Ofloxacin otic drops
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Neomycin-polymyxin B otic drops
Number of subjects: 306

Group type: COMPARATOR
Intervention: No postoperative otic drop prophylaxis (Control group)
Number of subjects: 306
Study: 14574830

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg 3 times daily for 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg 3 times daily for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylphenidate (both dosages)
Number of subjects: 30
Study: 10782522

Group type: EXPERIMENTAL
Intervention: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.pt.) - D. farinae (D.f) 50/50 extract, mean cumulative dose of 90,000 IR (2.2 mg of Der p 1 and 1.7 mg of Der f I) for 24 months.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo treatment for 24 months.
Number of subjects: 75
Study: 8633933

Group type: EXPERIMENTAL
Intervention: Retrograde warm blood cardioplegia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard cold topical irrigation
Number of subjects: 34
Study: 1727165

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg bolus and 5.4 mg/kg/hr for 23 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (5.4 mg/kg bolus and 4.0 mg/kg/hr for 23 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone or Naloxone
Number of subjects: 0
Study: 6376653

Group type: EXPERIMENTAL
Intervention: 14-valent streptococcus pneumoniae polysaccharide vaccine
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Saline as placebo
Number of subjects: 1273
Study: 29439711

Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 330

Group type: COMPARATOR
Intervention: Surgical liver resection
Number of subjects: 330
Study: 27295927

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediately loaded mandibular overdenture
Number of subjects: 2

Group type: COMPARATOR
Intervention: Delayed implant placement with immediately loaded mandibular overdenture
Number of subjects: 2
Study: 25428140

Group type: EXPERIMENTAL
Intervention: Treatment for ADHD symptoms and IPV, duration of treatment is one year with assessments at t0, 8, 16, 24, and 52 weeks.
Number of subjects: 0
Study: 24341093

Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium iv at 1.0 g 30 minutes before complete urodynamic examination
Number of subjects: 256

Group type: COMPARATOR
Intervention: No pre-treatment (Control)
Number of subjects: 256
Study: 20026265

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/d
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1489
Study: 18084691

Group type: EXPERIMENTAL
Intervention: 50 mg daily oral DHEA supplementation for one year
Number of subjects: 225
Study: 16810592

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam plus pethidine
Number of subjects: 100
Study: 12754879

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 500000
Study: 11140880

Group type: EXPERIMENTAL
Intervention: Hu23F2G
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9344324

Group type: EXPERIMENTAL
Intervention: Doxorubicin or epirubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dacarbazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin-ifosfamide combination chemotherapy
Number of subjects: 0
Study: 1416422

Group type: EXPERIMENTAL
Intervention: 40% O2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 12
Study: 3927763

Group type: EXPERIMENTAL
Intervention: alfentanil 7.5 micrograms/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: fentanyl 1.5 micrograms/kg
Number of subjects: 20
Study: 31375613

Group type: EXPERIMENTAL
Intervention: CCKO intervention (dedicated key workers and coordinated shared care plans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCKO intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 28295802

Group type: EXPERIMENTAL
Intervention: Cognitive therapy based on the Clark and Wells model
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Change in metacognitive beliefs
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Change in cognitive beliefs
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Change in self-consciousness
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Change in metacognition
Number of subjects: 46
Study: 26045397

Group type: EXPERIMENTAL
Intervention: Visual Imagery (VI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Kinesthetic Imagery (KI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mental Arithmetic Task (MAT)
Number of subjects: 24
Study: 24290734

Group type: EXPERIMENTAL
Intervention: LEP-ETU (liposome-entrapped paclitaxel)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Paclitaxel formulated with polyethoxylated castor oil (reference)
Number of subjects: 58
Study: 21508389

Group type: EXPERIMENTAL
Intervention: CAPOX treatment (capecitabine plus oxaliplatin) with bevacizumab
Number of subjects: 81
Study: 20112562

Group type: EXPERIMENTAL
Intervention: Poking reduction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 80
Study: 16669956

Group type: EXPERIMENTAL
Intervention: Alicaforsen enema (240 mg daily for 6 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 15571956

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for three months followed by 1 mg daily for five years
Number of subjects: 24
Study: 11256555

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (270 microg four times daily) for 2 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo after 2 weeks of inhaled albuterol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9143863

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0‐2.0 mg.day‐1) for 2‐13 years
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine (2 mg) infusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (n = 5)
Number of subjects: 31
Study: 7960013

Group type: EXPERIMENTAL
Intervention: Head-up tilting in hypertensive subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Head-up tilting in control subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-frequency components in systolic blood pressure after tilting in hypertensive subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-frequency components in systolic blood pressure after tilting in control subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-frequency components in skin blood flow after tilting in hypertensive subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-frequency components in skin blood flow after tilting in control subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity in hypertensive subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baroreflex sensitivity in control subjects
Number of subjects: 40
Study: 3591854

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (frequency of exercise not specified)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 141
Study: 31034030

Group type: EXPERIMENTAL
Intervention: Cocoon warmer (CW)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Radiant warmer (RW)
Number of subjects: 125
Study: 30449513

Group type: EXPERIMENTAL
Intervention: Second-stage duodenal switch (DS)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Single-stage laparoscopic biliopancreatic diversion with duodenal switch (BPD-DS)
Number of subjects: 118

Group type: COMPARATOR
Intervention: First-stage biliopancreatic diversion with duodenal switch (BPD-DS)
Number of subjects: 118
Study: 26741384

Group type: EXPERIMENTAL
Intervention: Juvéderm Ultra (24 mg/mL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Restylane (20 mg/mL)
Number of subjects: 104
Study: 25335781

Group type: EXPERIMENTAL
Intervention: Anthocyanin intake (271 mg and 7.11 mg C3g eq) in S2 trial
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Anthocyanin intake (346 mg C3g eq) in L1 trial
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo in S2 trial
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo in L1 trial
Number of subjects: 131
Study: 23789738

Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided femoral nerve block
Number of subjects: 110

Group type: COMPARATOR
Intervention: Fascia iliaca compartment block
Number of subjects: 110
Study: 21080967

Group type: EXPERIMENTAL
Intervention: Genuine EA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 48
Study: 18207167

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 100
Study: 16340726

Group type: EXPERIMENTAL
Intervention: Dynamic 133Xe SPECT
Number of subjects: 49
Study: 14604144

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiber-optic transillumination (FOTI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bite-wing radiographic assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct visual inspection after tooth separation
Number of subjects: 0
Study: 10965103

Group type: EXPERIMENTAL
Intervention: Cefpirome (CPM) 2 g i.v. every 12 h
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every 8 h
Number of subjects: 69
Study: 8648203

Group type: EXPERIMENTAL
Intervention: Schwarz (SW9) strain of measles vaccine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Schwarz (SW6) strain of measles vaccine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) strain of measles vaccine
Number of subjects: 88
Study: 1442917

Group type: EXPERIMENTAL
Intervention: Cefotetan, 2 gm intravenously every 12 hours
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cefoxitin, 2 gm intravenously every 6 hours
Number of subjects: 140
Study: 6308068

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (20 mg b.i.d.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg b.i.d.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (20 mg b.i.d.) and Hydrochlorothiazide (25 mg b.i.d.) in combination
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30287097

Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Number of subjects: 1982

Group type: COMPARATOR
Intervention: Saline Solution
Number of subjects: 1982
Study: 30587084

Group type: EXPERIMENTAL
Intervention: Active tRNS (12 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tRNS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active tRNS
Number of subjects: 40
Study: 26558729

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX)
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2180
Study: 24518149

Group type: EXPERIMENTAL
Intervention: Automated algorithm for measuring medial temporal lobe (MTL) volume
Number of subjects: 150

Group type: COMPARATOR
Intervention: FreeSurfer segmentation tools
Number of subjects: 150
Study: 19342396

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15133294

Group type: EXPERIMENTAL
Intervention: Radon therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermal therapy
Number of subjects: 0
Study: 12575588

Group type: EXPERIMENTAL
Intervention: TWP combined with MT (TWP 10 mg orally, 3 times a day; MT 7.5 mg orally once a week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: MT (15 mg orally, once every week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TWP combined with MT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (MT only)
Number of subjects: 70
Study: 9782544

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 9

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 9

Group type: COMPARATOR
Intervention: Anti-gravity suit (anti-G)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Elastic stockings and abdominal binder
Number of subjects: 9

Group type: COMPARATOR
Intervention: Functional electrical stimulation of the leg muscles
Number of subjects: 9
Study: 7874655

Group type: EXPERIMENTAL
Intervention: DIB positive subjects (n=132)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: DIBR scoring levels
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Self-report measures of problematic behaviors, symptoms, and social adaptation
Number of subjects: 171
Study: 3202391

Group type: EXPERIMENTAL
Intervention: Metras catheter (MC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional fiberoptic bronchoscope (FB)
Number of subjects: 25
Study: 12066096

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 36
Study: 30554600

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% twice daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% twice daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% once daily
Number of subjects: 247

Group type: COMPARATOR
Intervention: Vehicle cream twice daily
Number of subjects: 247

Group type: COMPARATOR
Intervention: Vehicle cream once daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tapinarof cream
Number of subjects: 247
Study: 29635949

Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive control (nonattenders)
Number of subjects: 0
Study: 26628383

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Warfarin (n=814)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Normal BMI (18.5-25 kg/m²)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Overweight (BMI 25-30 kg/m²)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Obese (BMI ≥30 kg/m²)
Number of subjects: 1588
Study: 24885486

Group type: EXPERIMENTAL
Intervention: HNCP (H&N Cancer Survivor Self‐management Care Plan) delivered by trained oncology nurses
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Written resource (information)
Number of subjects: 120
Study: 23160920

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (multiple doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (both single and multiple doses)
Number of subjects: 10
Study: 20521399

Group type: EXPERIMENTAL
Intervention: ASUMA Project intervention group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 18630653

Group type: EXPERIMENTAL
Intervention: Vicarious intergroup contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vicarious intergroup contact with authority figure support
Number of subjects: 0

Group type: COMPARATOR
Intervention: No contact condition
Number of subjects: 0
Study: 15776832

Group type: EXPERIMENTAL
Intervention: terazosine (5 mg/day, n = 29)
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo (n = 22)
Number of subjects: 51
Study: 12431195

Group type: EXPERIMENTAL
Intervention: Clostridium difficile-specific IgG (CDIgG) measurement using ELISA in atopic wheezy infants
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (non-atopic, no history of wheeze)
Number of subjects: 390
Study: 10512904

Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (4.5 mg bolus followed by 0.75 mg/h infusion for 12 hours)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (6 mg bolus followed by 1 mg/h infusion)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (7.5 mg bolus)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (3 mg, 4.5 mg, 6 mg, 7.5 mg bolus doses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7860749

Group type: EXPERIMENTAL
Intervention: 0.5 mg draflazine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adenosine dosages (0.15, 0.5, 1.5, 5, 15, and 50 micrograms/100 ml forearm per min)
Number of subjects: 12
Study: 1781051

Group type: EXPERIMENTAL
Intervention: Gitadyl (a herbal medicine containing 110 mg fever few, 90 mg American aspen, and 60 mg milfoil)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ibuprofen (Ibumetin) 1,200 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ibuprofen (Ibumetin)
Number of subjects: 35
Study: 6161534

Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31825471

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (titrated to 97/103 mg twice daily)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Switching from enalapril to sacubitril/valsartan after week 8
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: In-hospital initiation of sacubitril/valsartan
Number of subjects: 881

Group type: COMPARATOR
Intervention: Enalapril (titrated to target dose, 10 mg twice daily)
Number of subjects: 881
Study: 30833321

Group type: EXPERIMENTAL
Intervention: Online training resource for estimating survival in palliative care patients.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no access to the online training resource).
Number of subjects: 128
Study: 28169450

Group type: EXPERIMENTAL
Intervention: Cemented prostheses (three designs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cementless prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hip resurfacing prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All prostheses except hip resurfacing
Number of subjects: 0
Study: 27151378

Group type: EXPERIMENTAL
Intervention: Low-dose CD34+ stem cells (1×10^5 CD34/kg body weight)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: High-dose CD34+ stem cells (5×10^5 CD34/kg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low-dose CD34+ stem cells
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: High-dose CD34+ stem cells
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control
Number of subjects: 167
Study: 24416197

Group type: EXPERIMENTAL
Intervention: hypertonic saline/told hypertonic saline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hypertonic saline+lidocaine/told hypertonic saline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hypertonic saline+placebo/told hypertonic saline+pain killer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: hypertonic saline+lidocaine/told hypertonic saline+pain killer
Number of subjects: 48
Study: 22009072

Group type: EXPERIMENTAL
Intervention: High n-3 fatty acids
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: High MN intervention
Number of subjects: 598
Study: 19512866

Group type: EXPERIMENTAL
Intervention: Nefopam (100 ng/ml) and Clonidine (2.5 microg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nefopam (100 ng/ml) and Alfentanil (150 ng/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study: 17472199

Group type: EXPERIMENTAL
Intervention: Social phobia group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Major depression group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 54
Study: 14747165

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (expectant management)
Number of subjects: 104
Study: 12324985

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New patterns of insulin use
Number of subjects: 0
Study: 9649911

Group type: EXPERIMENTAL
Intervention: Breathing against an inspiratory threshold (40% of maximal inspiratory pressure)
Number of subjects: 16
Study: 8088015

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (spontaneous drowsing)
Number of subjects: 42
Study: 2770513

Group type: EXPERIMENTAL
Intervention: Disk‐Criminator
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: three‐prong Aesthesiometer
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: paper clip
Number of subjects: 38